A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of
A combination of two drugs, which prompt the body’s immune system to identify and kill cancer cells, is a safe treatment for patients with advanced non-small cell lung cancer and has shown some signs of efficacy. Results from a phase I/II clinical trial in 25 patients, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets
Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer. Research published in the November issue of The Journal of Nuclear Medicine found that the new tracer, 99mTc-HYNIC-cMBP, produced clearer images in less time than currently used tracers and was more rapidly eliminated from the body,
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok